Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Thomas Jefferson University
This is a 14 day on treat/14 day off treatment randomized, double blind viral kinetic study of elvucitabine versus lamivudine administered once daily to HIV infected subjects with a documented M184V variant.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV infected, clinically stable, adults
HIVRNA 5000 -150,000, CD4 100
Genotypically documented M184V variant
Receiving stable ART.
You may not be if
Hep B
HIV-1 genotype for 4 protease inhibitors
HIV-1 genotype positive for 2 NNRTI mutations
Previous therapy with system myelosuppressive potential within 3 months of study start
Use of Epogen or Neupogen
History of cirrhosis
Alcohol or drug dependence
Inability to tolerate oral medication
Women who are pregnant or breast feeding
Clareo Health | Safety Study of Elvucitabine in HIV-1 Subjects
